Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation
Introduction Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2021-04-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933821008956/type/journal_article |
| _version_ | 1827753759222005760 |
|---|---|
| author | A. Galanopoulos E. Tsiolka P. Ntounas D. Mpelimpasakis D. Karakoutas N. Sidiropoulos I. Mpougiouklis K. Kyziridis E. Papalexi |
| author_facet | A. Galanopoulos E. Tsiolka P. Ntounas D. Mpelimpasakis D. Karakoutas N. Sidiropoulos I. Mpougiouklis K. Kyziridis E. Papalexi |
| author_sort | A. Galanopoulos |
| collection | DOAJ |
| description |
Introduction
Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,a multimodal antidepressant, has shown encouraging data in achieving functional recovery, improving both mood and cognitive symptoms (Mahableshwarkar AR et al, 2015).
Objectives
The aim of the study was to assess the effectiveness of vortioxetine on mood symptoms, cognitive symptoms and functionality, assessed by patient-rated tools, in MDD outpatients in Greece.
Methods
In this non-interventional study, vortioxetine was administered as flexible dosing (5-20 mg/d). Mood symptoms, cognitive symptoms and functioning were assessed by the patient-rated scales PHQ-9, PDQ-D and SDS respectively, at baseline, 1 and 3 months. Repeated measures analysis of variance and t-test were used for the statistical analyses.
Results
336 patients participated in the study. PHQ-9 score ±SD decreased from 16.1±5.3, to 10.0±5.7 and 4.6±4.5, PDQ-D score ±SD decreased from 37.3±16.6 to 23.1±14.8 and 12.0±10.6, SDS Score ±SD decreased from 18.7±5.3 to 12.9±5.9 and to 7.8±6.5, at baseline, 1 and 3 months, respectively. The 3 SDS subscales: work/school life improved from 5.8±2.4 to 4.2±2.2 and 2.6±2.2, social life improved from 6.6±2.0 to 4.5±2.2 and 2.7±2.3 and family life improved from 6.3±2.0 to 4.3±2.1 and 2.6±2.3 -baseline, 1 and 3 months, respectively (p<0.001 for all paired comparisons).
Conclusions
MDD patients in Greece treated with vortioxetine significantly improved on mood symptoms, cognitive symptoms and functioning, enriching the already published efficacy data which is mostly based on clinician-rated scales.
Conflict of interest
A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas.
|
| first_indexed | 2024-03-11T07:39:44Z |
| format | Article |
| id | doaj.art-0c170db11f6748628860427c69cac452 |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:39:44Z |
| publishDate | 2021-04-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-0c170db11f6748628860427c69cac4522023-11-17T05:08:43ZengCambridge University PressEuropean Psychiatry0924-93381778-35852021-04-0164S334S33410.1192/j.eurpsy.2021.895Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluationA. Galanopoulos0E. Tsiolka1P. Ntounas2D. Mpelimpasakis3D. Karakoutas4N. Sidiropoulos5I. Mpougiouklis6K. Kyziridis7E. Papalexi8Medical, Lundbeck Hellas, Athens, GreecePsychiatric, Private Office, Athens, GreecePsychiatric, Private Office, Athens, GreecePsychiatric, Private Office, Athens, GreecePsychiatric, Private Office, Thesaloniki, GreecePsychiatric, Private Office, Thesaloniki, GreecePsychiatric, Private Office, Thesaloniki, GreecePsychiatric, Private Office, Thesaloniki, GreeceMedical, Lundbeck Hellas, ATHENS, Greece Introduction Functional recovery is the contemporary treatment goal in Major Depressive Disorder (MDD). Although consistency among physician and patient expectations may influence the therapeutic result (Demyttenaere K et al, 2011), patients’ perceptions are not always fully captured. Vortioxetine,a multimodal antidepressant, has shown encouraging data in achieving functional recovery, improving both mood and cognitive symptoms (Mahableshwarkar AR et al, 2015). Objectives The aim of the study was to assess the effectiveness of vortioxetine on mood symptoms, cognitive symptoms and functionality, assessed by patient-rated tools, in MDD outpatients in Greece. Methods In this non-interventional study, vortioxetine was administered as flexible dosing (5-20 mg/d). Mood symptoms, cognitive symptoms and functioning were assessed by the patient-rated scales PHQ-9, PDQ-D and SDS respectively, at baseline, 1 and 3 months. Repeated measures analysis of variance and t-test were used for the statistical analyses. Results 336 patients participated in the study. PHQ-9 score ±SD decreased from 16.1±5.3, to 10.0±5.7 and 4.6±4.5, PDQ-D score ±SD decreased from 37.3±16.6 to 23.1±14.8 and 12.0±10.6, SDS Score ±SD decreased from 18.7±5.3 to 12.9±5.9 and to 7.8±6.5, at baseline, 1 and 3 months, respectively. The 3 SDS subscales: work/school life improved from 5.8±2.4 to 4.2±2.2 and 2.6±2.2, social life improved from 6.6±2.0 to 4.5±2.2 and 2.7±2.3 and family life improved from 6.3±2.0 to 4.3±2.1 and 2.6±2.3 -baseline, 1 and 3 months, respectively (p<0.001 for all paired comparisons). Conclusions MDD patients in Greece treated with vortioxetine significantly improved on mood symptoms, cognitive symptoms and functioning, enriching the already published efficacy data which is mostly based on clinician-rated scales. Conflict of interest A. Galanopoulos and E. Papalexi are full-time employees in Lundbeck Hellas. https://www.cambridge.org/core/product/identifier/S0924933821008956/type/journal_articleMoodFunctionalityPatient-ratedVortioxetine |
| spellingShingle | A. Galanopoulos E. Tsiolka P. Ntounas D. Mpelimpasakis D. Karakoutas N. Sidiropoulos I. Mpougiouklis K. Kyziridis E. Papalexi Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation European Psychiatry Mood Functionality Patient-rated Vortioxetine |
| title | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
| title_full | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
| title_fullStr | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
| title_full_unstemmed | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
| title_short | Improvements in mood symptoms, cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine: A patient-rated evaluation |
| title_sort | improvements in mood symptoms cognitive symptoms and functioning in outpatients with mdd in greece treated with vortioxetine a patient rated evaluation |
| topic | Mood Functionality Patient-rated Vortioxetine |
| url | https://www.cambridge.org/core/product/identifier/S0924933821008956/type/journal_article |
| work_keys_str_mv | AT agalanopoulos improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT etsiolka improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT pntounas improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT dmpelimpasakis improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT dkarakoutas improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT nsidiropoulos improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT impougiouklis improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT kkyziridis improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation AT epapalexi improvementsinmoodsymptomscognitivesymptomsandfunctioninginoutpatientswithmddingreecetreatedwithvortioxetineapatientratedevaluation |